Thrombotic Microangiopathies

TGD001 Treatment in Thrombotic Microangiopathies

Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura

Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome

Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA Center

Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy

TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients

Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

Longitudinal Cohort of Thrombosis and Hemostasis Diseases

Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies

Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma

Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab

Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients

Automated Surveillance, Alert, and Rapid Diagnosis of Thrombotic Microangiopathies: the ASARD-TMA Study

Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies

Ravulizumab and COVID-19

Construction of a Database for TMA

Study in Adult and Pediatric Patients With HSCT-TMA